Türk Tobias R, Voropaeva Eva, Kohnle Matthias, Nürnberger Jens, Philipp Thomas, Kribben Andreas, Heemann Uwe, Witzke Oliver
Department of Nephrology & Hypertension, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, D-45122 Essen, Germany.
Nephrol Dial Transplant. 2008 Jan;23(1):369-73. doi: 10.1093/ndt/gfm620. Epub 2007 Oct 23.
Ezetimibe has shown efficacy in the therapy of hypercholesterolemia in renal transplant patients. This is the first study investigating the effect of ezetimibe on renal function in kidney transplant recipients.
Fifty-six patients with statin-resistant hypercholesterolemia (total cholesterol >200 mg/dl) after renal transplantation received additional ezetimibe therapy (10 mg/day) for 12 months. A group receiving statin therapy (n=28) served as controls in this prospective study.
Total cholesterol and LDL cholesterol concentrations decreased significantly in the ezetimibe-treated patients but remained stable in the control group (delta total cholesterol: -24+/-49 mg/dl vs 19+/-49 mg/dl, P<0.01; delta LDL: -30+/-39 mg/dl vs -3+/-31 mg/dl, P<0.01). Mean creatinine clearance remained stable in ezetimibe-treated patients but decreased significantly in control group (delta Cockcroft-Gault: 0.9+/-7.3 ml/min vs - 4.8+/-12.8 ml/min, P=0.025; delta Modification of Diet in Renal Disease: -0.4+/-6.2 ml/min/1.73 m(2) vs 4.7+/-8.8 ml/min/1.73 m(2), P=0.033).
The data of our prospective case-control study suggest that ezetimibe appears to ameliorate the decline of renal function after renal transplantation.
依折麦布已在肾移植患者的高胆固醇血症治疗中显示出疗效。这是第一项研究依折麦布对肾移植受者肾功能影响的研究。
56例肾移植后他汀类药物抵抗性高胆固醇血症（总胆固醇>200mg/dl）患者接受了额外的依折麦布治疗（10mg/天），为期12个月。一组接受他汀类药物治疗的患者（n = 28）作为该前瞻性研究的对照组。
依折麦布治疗的患者总胆固醇和低密度脂蛋白胆固醇浓度显著降低，但对照组保持稳定（总胆固醇变化：-24±49mg/dl对19±49mg/dl，P<0.01；低密度脂蛋白变化：-30±39mg/dl对-3±31mg/dl，P<0.01）。依折麦布治疗的患者平均肌酐清除率保持稳定，但对照组显著降低（Cockcroft-Gault变化：0.9±7.3ml/min对-4.8±12.8ml/min，P = 0.025；肾脏病饮食改良法变化：-0.4±6.2ml/min/1.73m²对4.7±8.8ml/min/1.73m²，P = 0.033）。
我们前瞻性病例对照研究的数据表明，依折麦布似乎可改善肾移植后肾功能的下降。
